When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy is detected, ALTACE® should be discontinued as soon as possible. See WARNINGS: Fetal/neonatal morbidity and mortality.
Reduction in Risk of Myocardial Infarction, Stroke, and Death from Cardiovascular Causes
Ramipril and ramiprilat inhibit angiotensin-converting enzyme (ACE).
Altace is indicated for the ollowing:
REDUCTION IN RISK OF MYOCARDIAL INFARCTION, STROKE, AND DEATH FROM CARDIOVASCULAR CAUSES
Altace is indicated in patients 55 years or older at high risk of developing a major cardiovascular event because of a history of coronary artery disease, stroke, peripheral vascular disease, or diabetes that is accompanied by at least one other cardiovascular risk factor (hypertension, elevated total cholesterol levels, low HDL levels, cigarette smoking, or documented microalbuminuria), to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes. Altace can be used in addition to other needed treatment (such as antihypertensive, antiplatelet or lipid-lowering therapy).
ALTACE is indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics.
In using ALTACE, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that ALTACE does not have a similar risk. (See WARNINGS.)
In considering use of ALTACE, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients. (See WARNINGS, Angioedema.)
HEART FAILURE POST MYOCARDIAL INFARCTION
Ramipril is indicated in stable patients who have demonstrated clinical signs of congestive heart failure within the first few days after sustaining acute myocardial infarction. Administration of ramipril to such patients has been shown to decrease the risk of death (principally cardiovascular death) and to decrease the risks of failure-related hospitalization and progression to severe/resistant heart failure. (See CLINICAL PHARMACOLOGY, Heart Failure Post Myocardial Infarction for details and limitations of the survival trial.)
Published Studies Related to Altace (Ramipril)
Potential vascular mechanisms of ramipril induced increases in walking ability in
patients with intermittent claudication. 
CONCLUSIONS: Ramipril is associated with an increase in the biomarkers of
Olmesartan vs. ramipril in elderly hypertensive patients: review of data from two
published randomized, double-blind studies. 
Hypertension is a frequent condition among individuals over 65 years of age
worldwide and is one of the most important risk factors for cardiovascular (CV)
disease. Effective drug treatment of elderly hypertensives is usually associated
with a marked reduction in CV morbidity and mortality...
Effect of naproxen and acetaminophen on blood pressure lowering by ramipril,
valsartan and aliskiren in hypertensive patients. 
CONCLUSIONS: Both naproxen and acetaminophen can affect anti-hypertensive therapy
Randomized clinical trial of angiotensin-converting enzyme inhibitor, ramipril,
in patients with intermittent claudication. 
parameters in patients with peripheral arterial disease... CONCLUSION: Ramipril improved walking distance in patients with claudication;
Randomised trial of ramipril in repaired tetralogy of Fallot and pulmonary
regurgitation: the APPROPRIATE study (Ace inhibitors for Potential PRevention Of
the deleterious effects of Pulmonary Regurgitation In Adults with repaired
TEtralogy of Fallot). 
ramipril and its effects on cardiovascular function in these patients... CONCLUSIONS: Ramipril is a well tolerated therapy, improves biventricular
Clinical Trials Related to Altace (Ramipril)
Bioavailability Study of Ramipril 10 mg Capsules of Dr. Reddy's Laboratories Limited Under Fasting Conditions [Completed]
Bioavailability Study of Ramipril 10 mg Capsules of Dr. Reddy's Laboratories Limited, Under Non-Fasting Conditions [Completed]
Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy [Recruiting]
The purpose of this study is to determine whether the combination with ramipril and
clopidogrel leads to further improvement of endothelial function, reduction of oxidative
stress and reduction of vascular inflammation, compared with ramipril monotherapy, in
patients with Diabetes Mellitus type 2 and diabetic nephropathy.
Mechanisms of Ramipril Reduction in the Onset of Type 2 Diabetes [Terminated]
The study will be focused on determining the integrated in-vivo mechanisms responsible for
Ramipril's effects on delaying type 2 diabetes and restoring normal (blood sugar levels)
glycemia in patients with impaired glucose tolerance.
Hypothesis - Ramipril effects will delay the onset of type 2 diabetes and restore normal
glycemia in patients with impaired glucose tolerance.
Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients [Completed]
This prospective multicenter, double blind study will evaluate the efficacy and safety of
aliskiren versus ramipril in patients with moderate systolic essential hypertension.
Reports of Suspected Altace (Ramipril) Side Effects
Drug Interaction (46),
Renal Failure Acute (36),
Drug Ineffective (35),
Oedema Peripheral (21),
Palpitations (20), more >>
Page last updated: 2015-08-10